arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

RESMED INC

RMD
$221.91 ▼ -0.41 (-0.18%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
19 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
84
Health
Excellent
Bullish
auto_awesome

Analytical Summary

RESMED INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $32.3B
Dividend Yield 1.08%
Revenue Growth 9.9% →
Op. Margin 33.4% →
ROIC 21.4% →
FCF / Share $11.34 →
Trailing P/E 21.2x
Price / Book 4.9x
FCF Yield 5.1%
Debt / Equity 0.10
info Valuation on last close. End-of-day price, Sep 24, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.65B
↑ +9.9% —
Net Income Profit after all expenses
$1.52B
↑ +8.8% —
Operating Margin Operating profit as % of sales
33.4%
↑ +1.9% 95th
FCF / Share Free cash flow per share
$11.34
— +0.1% —
Long-Term Debt Long-term obligations
$399.42M
↓ -39.3% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
93
Returns →
84
Financial Health →
86
Cash Quality ↑
63

Dividend History

Dividend / share · sourced from SEC filings
$2.40 Latest / share
+13.2% YoY
+7.2% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 19 years · 70 quarters